Skip Navigation



QJM Advance Access published online on October 13, 2006
QJM, doi:10.1093/qjmed/hcl101
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/11/723    most recent
hcl101v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Edwards, N.C.
Right arrow Articles by Townend, J.N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edwards, N.C.
Right arrow Articles by Townend, J.N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Review

The treatment of coronary artery disease in patients with chronic kidney disease

N.C. Edwards 1 *, R.P. Steeds 2, C.J. Ferro 3, and J.N. Townend 2

1 From the Department of Cardiovascular Medicine, University of Birmingham, Birmingham, UK
2 From the Department of Cardiology, Queen Elizabeth Hospital, Birmingham, UK
3 From the Department of Nephrology, Queen Elizabeth Hospital, Birmingham, UK

* To whom correspondence should be addressed.
N.C. Edwards, E-mail: N.C.Edwards{at}bham.ac.uk


  Abstract

Premature cardiovascular disease is the largest cause of mortality, and a major cause of morbidity, in patients with chronic kidney disease (CKD). Patients with end-stage kidney disease (ESKD) are at extreme risk, but cardiovascular event rates are increased even in early CKD. There is little controlled trial evidence on which to base treatment, as most therapeutic trials have excluded CKD patients. Current treatment strategies are therefore based upon small prospective studies or retrospective analyses of controlled trials and registry data. It is thus unclear whether CKD patients benefit from modern secondary preventive treatments in the same manner as patients with normal renal function. There is a need for randomized trials to identify effective drugs to prevent and treat coronary artery disease in CKD. Revascularization by CABG in CKD has been widely reported in registry data to provide better results than medical treatment or angioplasty. Recent angioplasty data in patients with CKD, however, show improving results, and the risks of CABG in CKD remain high. It is not clear which revascularization technique has a better outcome in patients ‘equally suitable’ on angiographic criteria for either procedure. The high rate of late adverse cardiovascular events after both CABG and angioplasty accentuates the need for effective secondary preventive therapy disease in these high-risk patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
I. F. Nevis, A. Mathew, R. J. Novick, C. R. Parikh, P. J. Devereaux, M. K. Natarajan, A. V. Iansavichus, M. S. Cuerden, and A. X. Garg
Optimal Method of Coronary Revascularization in Patients Receiving Dialysis: Systematic Review
Clin. J. Am. Soc. Nephrol., February 1, 2009; 4(2): 369 - 378.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.